ASIA unversity:Item 310904400/8200
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 94286/110023 (86%)
Visitors : 21661797      Online Users : 446
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/8200


    Title: Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression
    Authors: Yu, YL (Yu, Yung-Luen);Wei, CW (Wei, Chyou-Wei);Chen, YL (Chen, Yi-Lin);Chen, MHC (Chen, Mark Hung-Chih);Yiang, GT (Yiang, Giou-Teng)
    Contributors: Department of Biotechnology
    Keywords: RECOMBINANT ADENOASSOCIATED VIRUS;ACTIVATED KILLER-CELLS;GENE-THERAPY;TUMOR-GROWTH;IN-VIVO;IL-15;VECTORS;PURIFICATION;LYMPHOCYTES;SUPPRESSION
    Date: 2010-02
    Issue Date: 2010-03-26 02:28:59 (UTC+0)
    Publisher: Asia University
    Abstract: Recombinant adenovirus-associated vector serotype 2 (rAAV2) is one of the most promising gene transfer vectors due to its advantage of causing non-pathogenic infection, low immunogenicity, and long-term gene expression in human clinical trials. Human interleukin 15 (hIL15) has been implicated in modulation of antitumor activity of lymphokine-activated killer (LAK) cells, including T cells and NK cells. In this study, the rAAV2-hIL15 vector was produced and subjected for treatment with xenograft JC breast cancer model. Results showed that tumor onset was significantly delayed, the tumor growth was suppressed, and the lifespan of tumor-bearing mice were prolonged by rAAV2-h1L15. In addition, rAAV2-hIL15 was able to produce a substantial expression of IL15 protein that ultimately activated the cytotoxic activity of LAK cells. Furthermore, prominent apoptosis was observed in tumor lesions following injection of rAAV2-hIL15. Taken together, our results suggested that rAAV2-hIL15 appears as a new potential therapeutic tool for breast cancer immunotherapy.
    Relation: INTERNATIONAL JOURNAL OF ONCOLOGY 36 (2): 365-370
    Appears in Collections:[Department of Biotechnology] Journal Article

    Files in This Item:

    File Description SizeFormat
    5.docx0KbUnknown441View/Open
    5.dot43KbUnknown472View/Open
    310904400-8200.doc36KbMicrosoft Word556View/Open


    All items in ASIAIR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback